Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab

Inflammatory Bowel Diseases

Volumn 22, Issue 2, 2016, Pages 397-401

  Harris, Kimberly A ^a   Horst, Sara ^a   Gadani, Akash ^b   Nohl, Anne ^a   Annis, Kim ^a   Duley, Caroline ^a   Beaulieu, Dawn ^a   Ghazi, Leyla ^a,b   Schwartz, David A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

biologic therapy; Crohn's disease; inflammatory bowel disease; ustekinumab

Indexed keywords

BUDESONIDE; C REACTIVE PROTEIN; DIPHENHYDRAMINE; IMMUNOMODULATING AGENT; METHYLPREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; DERMATOLOGICAL AGENT;

ADULT; AGED; ANUS DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COLON DISEASE; COLONOSCOPY; CROHN DISEASE; DISEASE DURATION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOSCOPY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INFECTION; MALE; MULTICENTER STUDY (TOPIC); PATIENT HISTORY OF SURGERY; PATIENT PREFERENCE; PELVIS ABSCESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFRACTORY CROHN DISEASE; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SMALL INTESTINE DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; URTICARIA; ADOLESCENT; CHILD; DRUG EFFECTS; DRUG RESISTANCE; MIDDLE AGED; PRESCHOOL CHILD; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; DERMATOLOGIC AGENTS; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; USTEKINUMAB; YOUNG ADULT;

EID: 84955581975     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000624     Document Type: Article

References (22)

1. Hou JK, Kramer JR, Richardson P, et al. The incidence and prevalence of inflammatory bowel disease among U.S. veterans: a national cohort study. Inflamm Bowel Dis. 2013;19:1059-1064.
2. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380: 1590-1605.
3. Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroentero-logical Association Institute guideline on the use of thiopurines, metho-trexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenter-ology. 2013;145:1459-1463.
4. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
5. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644-659.
6. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
7. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
8. Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol. 2006;12:5606-5610.
9. Neurath MF. IL-23: a master regulator in Crohn disease. Nat Med. 2007; 13:26-28.
10. Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3:535-545.
11. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007; 356:580-592.
12. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of uste-kinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-1674.
13. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of usteki-numab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-1684.
14. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human inter-leukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-640.
15. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780-789.
16. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Uste-kinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008;135:1130-1141.
17. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012;367:1519-1528.
18. A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1). Available at: https://clinicaltrials.gov/ct2/show/NCT01369329. Accessed February 2, 2015.
19. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinu-mab Induction Therapy in Subjects with Moderately to Severely Active Crohn's Disease (UNITI-2). Available at: https://clinicaltrials.gov/ct2/show/NCT01369342. Accessed February 2, 2015.
20. A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease (IM-UNITI). Available at: https://clinicaltrials.gov/ct2/show/NCT01369355. Accessed February 2, 2015.
21. Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease-the McGill experience. J Crohns Colitis. 2014;8:1516-1522.
22. Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-g-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63:567-577.